MedTrace Logo

International Study of High-Risk Patients for Hepatocellular Carcinoma Using Liquid Biopsy

NCT05342350 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 360

Last updated 2025-06-12

No results posted yet for this study

Summary

This study has two purposes. One is to conduct a phase IV biomarker validation study in which the investigators will prospectively survey a cohort of patients at risk for liver cancer using semi-annual abdominal ultrasound and GALAD Score for 5 years. The GALAD score is a serum biomarker-based panel that can aid in early detection among patients with a high risk for liver cancer. One is to establish a bio-repository of longitudinally collected bio-specimens from patients with fibrosis/cirrhosis as a reference set for future research.

Conditions

Interventions

OTHER

GALAD Score

GALAD score, a blood-based biomarker panel (gender, age, AFP, AFP-L3%, DCP)

Sponsors & Collaborators

  • King Faisal Specialist Hospital & Research Center

    collaborator OTHER

  • Medic Medical Center (Viet Nam)

    collaborator UNKNOWN

  • Johns Hopkins University

    lead OTHER

Principal Investigators

  • Doan Dao, MD · Johns Hopkins University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-15
Primary Completion
2025-06-07
Completion
2025-06-07

Countries

  • Saudi Arabia
  • Vietnam

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05342350 on ClinicalTrials.gov